The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have shown that DPP4i exhibit cardiovascular neutrality in T2DM patients.”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across the trials of this drug class, there appears to be no interaction by age-group (110-112).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]
The cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [313]
The cited source says what the claim attributes to it.
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [19]
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [31]
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [215]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“In mice, GLP-1 causes vasodilation through both GLP-1 receptor-dependent and -independent mechanisms.211”
From The Vasculature in Prediabetes (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,006
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 39
Zannad, F. M., Stough, W. G., Lipicky, R. J., Tamargo, J. L., Bakris, G. L., BORER, J. S., García, M. D. L. A. A., Hadjadj, S., Köenig, W., Kupfer, S., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw007 · Cited by 38
Jax, T. W., Stirban, A. O., Terjung, A., Esmaeili, H. A., Berk, A., Thiemann, S., CHILTON, R. J., von Eynatten, M., & Marx, N. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0493-3 · Cited by 38
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
Kim, N. H., Choi, J., Kim, N. H., Choi, K. M., Baik, S. H., Lee, J., & Kim, S. G. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.03.004 · Cited by 38
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 38
SAIS Study Group, Kitao, N., Miyoshi, H., Furumoto, T., Ono, K., Nomoto, H., Miya, A., Yamamoto, K., Inoue, A., Tsuchida, K., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0607-6 · Cited by 38
Hanssen, N. M. J., & Jandeleit-Dahm, K. A. M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842339 · Cited by 39
Solid-State Characterization of Different Crystalline Forms of Sitagliptin
Stofella, N. C. F., Veiga, A., Oliveira, L. J., Montin, E. F., Andreazza, I. F., Filho, M. A. S. C., Bernardi, L. S., de Oliveira, P. R., & Murakami, F. S. (2019) · Materials · doi:10.3390/ma12152351 · Cited by 38
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 40
Segar, M. W., Patel, K. V., Hellkamp, A. S., Vaduganathan, M., Lokhnygina, Y. V., Green, J. B., Wan, S., Kolkailah, A. A., Holman, R. R., Peterson, E. D., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024094 · Cited by 38
Self-citationCardiac and Renovascular Complications in Type 2 Diabetes — Is There Hope?
Ingelfinger, J. R., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejme1607413 · Cited by 38
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 38
Aroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 37
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 39
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Knudsen, J. S., Baggesen, L. M., Lajer, M., Nurkanovic, L., Ustyugova, A., Sørensen, H. T., & Thomsen, R. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229621 · Cited by 39
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 39
Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats
Aziz, T. A. (2021) · Cancer Management and Research · doi:10.2147/cmar.s300495 · Cited by 37
Roessler, J., Leistner, D. M., Landmesser, U., & Haghikia, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.018 · Cited by 39
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 37
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 38
Gao, H. X., Regier, E. E., & Close, K. L. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12377 · Cited by 36
Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure
Koyani, C. N., Kolesnik, E., Wölkart, G., Shrestha, N., Scheruebel, S., Trummer, C., Zorn‐Pauly, K., Hammer, A., Lang, P., Reicher, H., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.021 · Cited by 36
The European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 40
Gallwitz, B. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 36
Bekki, M., Tahara, N., Tahara, A., Igata, S., Honda, A., Sugiyama, Y., Nakamura, T., Sun, J., Kumashiro, Y., Matsui, T., et al. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180515154555 · Cited by 36
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 39
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 36
McAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Self-citationImpact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 36
Zhou, Y., Wang, H., Man, F., Guo, Z., Xu, J., Yan, W., Li, J., Pan, Q., & Wang, W. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6831-9 · Cited by 36
Type 2 Diabetes Medication Review
Sterrett, J., Bragg, S. W., & Weart, C. W. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.019 · Cited by 38
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 35
Schernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 38
Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus
Akoumianakis, I., & Antoniades, C. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7421 · Cited by 37
Fei, Y., Tsoi, M. F., Kumana, C. R., Cheung, T. T., & Cheung, B. M. Y. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.039 · Cited by 35
Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis
Lee, S., Lee, S., Choi, B., Kim, Y., Oh, S. J., Choi, H., Kim, E. K., Kim, D., Cho, G., Song, J., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-317024 · Cited by 35
Sun, S., Hisland, L., Grenet, G., Gueyffier, F., Cornu, C., Jaafari, N., & Boussageon, R. (2021) · Therapies · doi:10.1016/j.therap.2021.10.002 · Cited by 39
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 35
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 38
Kunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 35
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 36
Tong, L., & Adler, S. G. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457397 · Cited by 36
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 34
Treatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 35
Hsu, P., Sung, S., Cheng, H., Shin, S.-J., Lin, K., Chong, K., Yen, F., Yu, B.-H., Huang, C.-T., & Hsu, C.-C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00040 · Cited by 35
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 35
Kwon, M. J., Lee, Y., Jung, H. S., Shin, H. M., Kim, T. N., Lee, S. H., Rhee, B. D., Kim, M.-K., & Park, J. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.006 · Cited by 34
Mechanick, J. I., Adams, S., Davidson, J. A., Fergus, I. V., Galindo, R. J., McKinney, K. H., Petak, S. M., Sadhu, A., Samson, S. L., Vedanthan, R., et al. (2019) · Endocrine Practice · doi:10.4158/ps-2019-0080 · Cited by 35
Patorno, E., Najafzadeh, M., Pawar, A., Franklin, J. M., Déruaz‐Luyet, A., Brodovicz, K. G., Ortiz, A. J. S., Bessette, L. G., Kulldorff, M., & Schneeweiß, S. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.103 · Cited by 34
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 36
Berezin, A. Е., & Berezin, A. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00835-9 · Cited by 34
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
Regan, J. A., Truby, L., Tahir, U. A., Katz, D. H., Nguyen, M., Kwee, L. C., Deng, S., WILSON, J. G., Mentz, R. J., Kraus, W. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24226-1 · Cited by 34
Self-citationEnzan, N., Matsushima, S., Kaku, H., Tohyama, T., Nagata, T., Ide, T., & Tsutsui, H. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.09.015 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Ou, H., Chang, K., Li, C., & Wu, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13241 · Cited by 34
Raschi, E., Poluzzi, E., Koci, A., Antonazzo, I. C., Marchesini, G., & Ponti, F. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.02.006 · Cited by 33
Engel, S. S., Suryawanshi, S., Stevens, S. R., Josse, R. G., Cornel, J. H., Jakubonienė, N., Riefflin, A., Tankova, T. I., Wainstein, J., Peterson, E. D., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12983 · Cited by 34
Self-citationThe regulatory role of DPP4 in atherosclerotic disease
Duan, L., Rao, X., Xia, C. Q., Rajagopalan, S., & Zhong, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0558-y · Cited by 33
Gautam, S., Agiro, A., Barron, J. O., Power, T. P., Weisman, H., & White, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0575-x · Cited by 33
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1185 · Cited by 33
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Giugliano, D., Maiorino, M. I., Longo, M., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Endocrine · doi:10.1007/s12020-019-01931-y · Cited by 33
Gao, P., Li, L., Wei, X., Wang, M., Hong, Y., Wu, H., Shen, Y., Ma, T., Wei, X., Zhang, Q., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13778 · Cited by 33
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Terasaki, M., Yashima, H., Mori, Y., Saito, T., Matsui, T., Hiromura, M., Kushima, H., Osaka, N., Ohara, M., Fukui, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134811 · Cited by 33
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 33
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Self-citationIncretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Kawase, H., Bando, Y., Nishimura, K., Aoyama, M., Monji, A., & Murohara, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.066 · Cited by 32
Barkas, F., Elisaf, M., Tsimihodimos, V., & Milionis, H. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.10.006 · Cited by 32
Tanaka, A., Shimabukuro, M., Okada, Y., Taguchi, I., Yamaoka‐Tojo, M., Tomiyama, H., Teragawa, H., Sugiyama, S., Yoshida, H., Sato, Y., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0532-8 · Cited by 32
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 35
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.05.007 · Cited by 34
Spencer, N. Y., Yang, Z., Sullivan, J. C., Klein, T., & Stanton, R. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200249 · Cited by 33
Mishriky, B. M., Powell, J. R., Wittwer, J. A., Chu, J., Sewell, K. B., Wu, Q., & Cummings, D. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13805 · Cited by 32
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 34
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32
Kim, Y., Levin, G., Nikolov, N. P., Abugov, R., & Rothwell, R. (2020) · Arthritis Care & Research · doi:10.1002/acr.24549 · Cited by 32
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 33
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 33
Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Ohm, B., Moneke, I., & Jungraithmayr, W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15967 · Cited by 35
Lyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 32
Saxagliptin: A Review in Type 2 Diabetes
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0473-z · Cited by 34
Histones and heart failure in diabetes
Yerra, V. G., & Advani, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2857-1 · Cited by 33
Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea
Coats, A. J. S. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0004 · Cited by 32
Heller, S. R., Buse, J. B., Ratner, R. E., Seaquist, E. R., Bardtrum, L., Hansen, C. T., Tutkunkardas, D., & Moses, A. C. (2019) · Diabetes Care · doi:10.2337/dc18-2361 · Cited by 33
Self-citationSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05508-1 · Cited by 31
Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems
Kaushal, A., Musafir, A., Sharma, G., Rani, S., Singh, R. K., Kumar, A., Bhadada, S. K., Barnwal, R. P., & Singh, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060777 · Cited by 31
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease
Remm, F., Franz, W., & Brenner, C. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv044 · Cited by 31
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 32
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 31
Williams, R., de Vries, F., Kothny, W., Șerban, C. I., López‐León, S., Chu, C., & Schlienger, R. G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12951 · Cited by 31
Hubers, S. A., Wilson, J. R., Yu, C., Nian, H., Grouzmann, E., Eugster, P. J., Shibao, C. A., Billings, F. T., Kerman, S. R. J., & Brown, N. J. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11498 · Cited by 31
Dawwas, G. K., Smith, S. M., & Park, H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0746-4 · Cited by 31
Metadata
- Authors
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Oxford (GB)
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- The University of Texas Southwestern Medical Center (US)
- Helmholtz Munich (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 232-242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142830692
- Semantic Scholar
- 5f5aabad35a6c6137b19d8640d5d6cafc91815e5
- Cited by
- 2,577
- References
- 16
- Citations by year
- 2026: 68 · 2025: 121 · 2024: 120 · 2023: 139 · 2022: 170 · 2021: 210 · 2020: 289 · 2019: 267 · 2018: 343 · 2017: 343 · 2016: 378 · 2015: 120
- FWCI
- 341.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by-nc-nd)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- South Australian Health and Medical Research Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sitagliptin, type 2 diabetes, cardiovascular disease, DPP-4 inhibitors, major adverse cardiovascular events, heart failure hospitalization, acute pancreatitis, pancreatic cancer, HbA1c, glycemic control, non-inferiority
- MeSH terms
- Sitagliptin Phosphate, Administration, Oral, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Heart Diseases, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Pyrazines, Triazoles, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
